
NIH abruptly terminates millions in research grants, defying court orders
Super added that the termination letters are also 'unlawful' because the NIH is imposing conditions on funding that did not exist at the time the grants were awarded.
Advertisement
The NIH did not respond to a request for comment.
Scientists say the letters began arriving last Friday and earlier this week, notifying them their funding was being canceled because it involved subjects that are 'unscientific,' do 'nothing to enhance the health of many Americans,' or do 'not enhance health, lengthen life, or reduce illness.'
Exactly how many NIH grants have been terminated is unclear.
With an annual budget of more than $45 billion, the NIH is the largest single public funder of biomedical research in the world, and
Among those whose research funding was terminated is Nancy Krieger, a professor of social epidemiology at the Harvard T.H. Chan School of Public Health. Her letter said she would not be receiving the last installment, roughly $650,000, of a five-year, $4 million award for honing time-efficient ways of asking patients about the discrimination they experience, including racism, sexism, sexual orientation, and age or weight discrimination.
Advertisement
'These are really important groups of people to study to understand how their life experiences are affecting their health,' Krieger said
.
The letter she received said her work ran afoul of the administration's anti-DEI rules, although Krieger said the research itself was not related to DEI.
'This is an assault not on just one little group of researchers. This is saying certain knowledge is not to be supported by the government,' Krieger said. 'It's the proverbial, 'If there's no data, there's no problem.' It means one can't document the harms.'
The letters sent to scientists said they had 30 days to appeal to the agency for reconsideration, which Krieger said she intends to do.
Krieger's research enrolled roughly 700 patients at three Boston community health centers including Fenway Health.
Dr. Kenneth Mayer, who heads the study arm at Fenway Health and is a professor at Harvard Medical School, said the cancellation of the grant would not immediately harm patients participating in the study. But, 'it could have an impact on patient health in the future,' he said. 'The whole point is to learn about biases. Some people avoid health care because they think they are going to be judged.'
He said it's possible the four years' worth of data already collected may be used, such as to develop training programs for doctors or educational materials for patients. 'This is just such an important kind of work,' he said.
An NIH official told the Globe that administrators who oversee grants were given barely an hour's notice of the terminations late last Friday before the notifications were sent out.
Advertisement
The official, who declined to be identified because they are not authorized to speak publicly, said they were aware of 24 such notices from four NIH institutes and centers, but said there are likely to be hundreds more.
This official shared a spreadsheet that showed 76 notices of funding opportunities over the past two years that the agency 'unpublished,'
meaning they were
effectively scrubbed from public databases, potentially eliminating the funding for them.
Brittany Charlton, associate professor and founding director of the LGBTQ Health Center of Excellence at Harvard T.H. Chan School of Public Health, has not had any research funding terminated but has heard directly from several scientists who did lose their funding. She said many will appeal.
Charlton said researchers are also working to partner with civil rights organizations as they challenge the legality of these executive orders.
'This goes beyond research on LGBTQ health and includes studies seeking to understand and address health issues affecting a wide range of other vulnerable communities,' Charlton said in a statement. 'Scientific inquiry is under siege and the public's health hangs in the balance as crucial studies vanish.'
Sean Arayasirikul, a medical sociologist and an associate professor in-residence in the department of Health, Society, and Behavior at University of California Irvine, received a termination letter last Friday that stopped funding halfway through a five-year study involving roughly 900 participants.
Arayasirikul's research studies how racism and discrimination affect people of color who are gay or transgender and need help with HIV prevention, substance use disorder, or mental health.
Advertisement
'That is one of the biggest priorities for HIV prevention today and not having these data and not having this knowledge hearkens back to a time when denialism around HIV was prevalent,' Arayasirikul said.
'I am starting to think now that I may lose my job and not exist in this field anymore and that's one thing,' said Arayasirikul. 'But to erase an entire generation of scholars who come from these communities, doing this work, the impact of that is immense.'
Kay Lazar can be reached at
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Upturn
an hour ago
- Business Upturn
Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress
By GlobeNewswire Published on June 23, 2025, 00:35 IST New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated with no safety concerns in adults and adolescents with haemophilia A, with or without inhibitors 1 . . Switching to Mim8 led to a sustained increase in thrombin generation into the normal range, but without causing thrombin levels that might pose a thrombotic risk 1 . . FRONTIER5 Patient-Reported Outcomes (PROs) assessment found the Mim8 pen-injector easy to use, with strong user preference over their emicizumab injection system 2 . . These results add to the overall safety profile of Mim8 based on the FRONTIER clinical trial programme3. Bagsværd, Denmark, 22 June 2025 – Novo Nordisk today presented results from the phase 3b FRONTIER5 trial showing that a direct switch to investigational Mim8 (denecimig) prophylaxis from emicizumab treatment, without a washout period or Mim8 loading dose, was well-tolerated with no safety concerns in adults and adolescents living with haemophilia A, with or without inhibitors1. Additionally, a FRONTIER5 Patient-Reported Outcomes (PROs) assessment found the Mim8 pen-injector easy to use, with an overall strong user preference for the pen-injector compared to the previous emicizumab injection system2,3. The results were presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington, D.C. In the study, the first Mim8 maintenance dose was administered on the next planned emicizumab dosing day. Patients were given the option of switching to once-monthly, once every two weeks or once-weekly dosing frequencies of Mim8, regardless of their prior dosing frequency1,3. Steady-state Mim8 concentration was achieved by Week 16, and emicizumab elimination was completed by Week 261. Switching to Mim8 led to a sustained increase in thrombin peak levels without an exaggerated thrombin response1. 'Continuous prophylactic coverage is critical to avoiding breakthrough bleeds in people living with haemophilia; with new non-factor therapeutic options, many people could have hesitations about switching treatment options. These data demonstrate that switching to Mim8 from emicizumab can be done without requiring a washout period,' said Allison P. Wheeler, MD, Washington Center for Bleeding Disorders, Seattle, WA. 'This is critical in ensuring that individuals maintain continuous protection against bleeding events as we seek to help address the ongoing needs of people living with this complex disease.' The open-label phase 3b FRONTIER5 study consisted of 61 adults and adolescents, aged 12 years and older, with haemophilia A. Mim8 was well-tolerated with no safety concerns. No thromboembolic events, hypersensitivity reactions, or treatment-emergent adverse events (TEAEs) leading to discontinuation were observed, and there was no clinical evidence of neutralising anti-Mim8 antibodies1. The PROs data from FRONTIER5 indicated a strong overall preference for the Mim8 pen-injector, with 97% (n=57/59) of patients reporting a 'very strong' or 'fairly strong' preference in comparison to their previous emicizumab injection system2. Of the participants who completed the Haemophilia Device Handling and Preference Assessment (HDHPA) questionnaire at week 26, 98% (n=58/59) found the Mim8 pen-injector 'very easy' or 'easy' to use, and 95% (n=56/59) found it 'much easier' or 'easier' compared with their previous administration method. All participants (100%) were 'extremely confident' or 'very confident' in using the pen-injector correctly, and most participants (83%; n=49/59) found it 'very easy' to inject the dose2. 'The FRONTIER5 safety and patient-reported outcomes data support Mim8 as a potential future treatment option for people living with haemophilia A and demonstrate our continued commitment to developing innovative treatment options for this community', said Stephanie Seremetis, chief medical officer and CVP for Haemophilia at Novo Nordisk. 'These results give valuable insights into haemophilia A management, highlight the feasibility of directly switching to Mim8 from emicizumab, and reveal a strong patient preference for the Mim8 pen-injector device.' Novo Nordisk expects to submit Mim8 for regulatory review during 2025. Data from the ongoing phase 3 FRONTIER programme will be disclosed at upcoming congresses and in publications in 2025 and 2026. About haemophilia Haemophilia is a rare inherited bleeding disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding4. It is estimated to affect approximately 1,125,000 people worldwide5. There are different types of haemophilia, which are characterised by the type of clotting factor protein that is defective or missing4. Haemophilia A is caused by a missing or defective clotting Factor VIII (FVIII), and haemophilia B is caused by a missing or defective clotting Factor IX4. Inhibitors are an immune system response to the clotting factors in replacement therapy. Currently, it is estimated that up to 30% of people living with severe haemophilia A develop inhibitors6 that can cause replacement therapies to stop working. About Mim8 Mim8 is an investigational FVIIIa mimetic bispecific antibody optimised with the aim to deliver improved potency and sustained efficacy across flexible dosing intervals up to once-monthly prophylaxis for people living with haemophilia A, with or without inhibitors7-10. Administered under the skin, Mim8 bridges Factor IXa and Factor X. This action replaces FVIII function, which helps restore the body's thrombin generation capacity into the normal range, helping blood to clot7,11. The use of Mim8 in people living with haemophilia A is investigational and not approved by regulatory authorities or available anywhere in the world. About the FRONTIER5 trial FRONTIER5 is a single-arm, open-label, 26-week, phase 3b trial evaluating the safety of switching from previous emicizumab prophylaxis treatment directly to Mim8 prophylaxis treatment using the Mim8 pen-injector in adults and adolescents with haemophilia A, with or without inhibitors3. The FRONTIER clinical programme investigates Mim8 as a prophylaxis treatment for people with haemophilia A, with or without inhibitors. This programme includes FRONTIER1, FRONTIER2, FRONTIER3, FRONTIER4 and FRONTIER53,12-15. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information _______________________ References Oldenberg J, Benson G, Chowdaryet P, et al. FRONTIER5 direct switch study: Safety of initiating Mim8 prophylaxis without washout of emicizumab. Oral presentation presented at the Congress of the International Society on Thrombosis and Haemostasis 2025; June 21-25 2025; Walter E. Washington Convention Center, Washington D.C., US. Session code 13686. Mahlangu J, Ahuja S, Cockrell E, et al. FRONTIER5 device handling and patient-reported outcomes. Oral presentation presented at the Congress of the International Society on Thrombosis and Haemostasis 2025; June 21–25 2025; Walter E. Washington Convention Center, Washington D.C., US. Session code 13786. A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER5). Available at: Last accessed: June 2025. MedlinePlus. Hemophilia. Available at: Last accessed: June 2025. Iorio A, Stonebraker JS, Chambost H, et al. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries. Ann Intern Med. 2019;171:540–546. doi: 10.7326/M19-1208. Kim JY, You CW. The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A. Blood Res. 2019;54:204-209. doi: 10.5045/br.2019.54.3.204. Ostergaard H, Lund J, Greisen PJ, et al. A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice. Blood. 2021;138:1258-1268. doi: 10.1182/blood.2020010331. Mancuso EM, et al. Efficacy and safety of Mim8 prophylaxis in adults and adolescents with hemophilia A with or without inhibitors: Phase 3, open-label, randomized, controlled FRONTIER2 study. Abstract presented at the International Society on Thrombosis and Haemostasis (ISTH) 2024 Congress. Kenet G, et al. Patient- and caregiver-reported outcomes with subcutaneous Mim8 prophylaxis in paediatric patients with haemophilia A with or without factor VIII inhibitors: phase 3 FRONTIER3 study. Abstract presented at the European Association for Haemophilia and Allied Disorders (EAHAD) 2025 Annual Congress. Session 6. Chowdary P, Banchev AM, Kavakli K, et al. Safety and Efficacy of Mim8 Prophylaxis Administered Once Every Two Weeks for Patients with Hemophilia A with or without Inhibitors: Interim Analysis of the FRONTIER4 Open-Label Extension Study. Abstract presented at the American Society of Hematology (ASH) 2024 Annual Congress. Session: 322. U.S. National Library of Medicine. F8 gene. MedlinePlus Genetics. Available at Last accessed: June 2025. A Research Study Investigating Mim8 in People With Haemophilia A (FRONTIER1). Available at: Last accessed: June 2025. A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors. Available at: Last accessed: June 2025. A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors. Available at: Last accessed: June 2025. A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER4). Available at: Last accessed: June 2025. Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.


New York Post
an hour ago
- New York Post
Why Ozempic users should be extra careful during heatwaves
Talk about melting the weight off. Summer may be filled with beach days and barbecues, but it can also bring blistering temperatures. This week, millions of Americans — including New Yorkers — are bracing for what forecasters are calling a 'very sweaty' heatwave. People who are on GLP-1s need to be on particularly high alert amidst the high degrees. New Africa – And people who are on weight loss drugs like Ozempic, Wegovy and Mounjaro need to be on particularly high alert amidst the high degrees. That's because these drugs work by suppressing appetite, which means they can wind up curbing thirst as well. This, in turn, can unwittingly lead to dehydration — a dangerous condition that can cause dizziness, headaches, low blood pressure, blurred vision, kidney problems and, in extreme cases, fatal heatstroke. Since eating normally stimulates saliva flow, eating less while on Ozempic can mean less stimulation to the salivary glands, which can in turn lead to dry mouth — another symptom of dehydration left unchecked. And if you've heard about Ozempic teeth, you know some of the most common side effects of GLP-1s pose their own dangers during a heatwave. 'You'll need to be extra careful about hydration during hot weather as these medications often cause nausea, vomiting or diarrhea — all of which can lead to fluid loss,' nutritional therapist Deborah Grayson told The Daily Mail. 'This is particularly important for new users of the weight loss medication, whose bodies are still adjusting.' 'You'll need to be extra careful about hydration during hot weather as these medications often cause nausea, vomiting or diarrhea — all of which can lead to fluid loss,' Grayson said. millaf – To remain vigilant, Grayson recommends the following: Drink plenty of water, even if you don't feel thirsty Put a timer on to remind you to hydrate Avoid alcohol and caffeine Avoid being outdoors during peak heat hours Eat easy-to-digest foods such as those on the BRAT diet In addition to suppressing thirst and potentially inducing vomiting/diarrhea, GLP-1s could mess with your body's ability to regulate body temperature, making it harder to tolerate heat. This is all the more reason to drink lots of water — sprinkle some electrolytes into the mix to stay hydrated longer. Use urine as your barometer — light yellow means you're in the clear, whereas darker colors are a bad sign. And avoid physical exertion, especially outside. It might be excruciatingly hot, but perhaps the heatwave is a good excuse to stay on your Ozempic butt for a bit.


The Hill
7 hours ago
- The Hill
Thanks to imported drugs, America has lost control of its medicine cabinet
America is facing a growing crisis in its medical system — not from a lack of talent or innovation, but from a breakdown in the control, safety and supply of essential medicines. Our growing reliance on imports is now driving serious drug shortages, destabilizing supply chains and increasingly making medications unsafe. At the root of it is a hard truth: We no longer have control of the medicines we depend on every day. In 2002, America manufactured 83.7 percent of the pharmaceuticals it consumed. By 2024, that number had dropped to just 37.1 percent. Meanwhile, the U.S. pharmaceutical trade deficit has soared, reaching a record $118.3 billion in 2024. We didn't just outsource manufacturing — we outsourced the sovereignty and safety of our health care system. This means that nearly two-thirds of America's pharmaceutical supplies are now imported. Most critical medications, such as generic drugs, now come from China and India. China controls 80 to 90 percent of the global supply of active pharmaceutical ingredients — the chemical building blocks of modern medicine. Even drugs labeled 'Made in the USA' often chemically originate in China. And India, which produces about half of America's finished generic drugs, relies on China for up to 80 percent of its active pharmaceutical not a supply chain — it's a ticking time something goes wrong, American patients suffer. In 2023, the Food and Drug Administration shut down a single Indian plant responsible for 50 percent of the U.S. supply of cisplatin, a critical chemotherapy drug, after uncovering a 'cascade of failure' in safety practices and shredded documents soaked in acid. With no domestic backup, patients nationwide had their treatments delayed. That wasn't a fluke. 40 percent of U.S. generic drugs have only one FDA-approved manufacturer. Because of that single chokepoint, when one factory fails, the whole system can crack. We are now seeing widespread drug shortages across the medical system. Hospital pharmacists report an average of 301 critical drug shortages at any given time. And 85 percent say these shortages are moderately or critically affecting care. Doctors often lack crucial medicines such as antibiotics, sedatives and cancer drugs. These aren't obscure drugs. They're foundational medicines. But America no longer makes them. Even when imported drugs do arrive, they're not always safe. A 2025 study found that Indian generics are 54 percent more likely to cause serious side effects than their U.S.-made counterparts. Indian factory violations have also been tied to at least eight U.S. patient deaths. China's record is equally disturbing. In 2008, dozens of Americans died after receiving contaminated heparin from Chinese suppliers. This isn't what the American people want. In a national survey, 85 percent of hospital pharmacists said they would pay more for safer generics. But under today's rules, price overshadows quality. Hospitals have little oversight of drug quality — and foreign producers face few consequences for cutting corners. Even the federal government is flying blind. A 2023 Department of Defense review found that 22 percent of essential military-use drugs had unknown ingredient sourcing. That's a national security April, the Trump administration took a necessary step by launching an investigation into generic pharmaceutical imports that correctly frames the issue as a national security threat. But that recognition alone isn't enough. To address this crisis, Washington should impose targeted tariffs on generic drugs from adversarial nations. It must also rebuild domestic pharmaceutical production through tax credits and long-term contracts. America urgently needs full transparency in drug labeling to disclose where drugs and their ingredients are made. The FDA must step up — with stronger enforcement abroad and a ban on imports from repeat safety violators. And to secure critical ingredients during market disruptions, Washington must pursue a long-term vision that includes a 'strategic pharmaceutical reserve.' This isn't just protectionism. It's a restoration of America's medical security. No nation can call itself sovereign if it can't produce its own medicines, and no patient is safe if their health care depends on quality control in a factory 8,000 miles decades, we were told that offshoring production would make things cheaper, smoother and more efficient. But America can no longer depend on unstable foreign suppliers. It's time to restore our pharmaceutical independence and take back control of our medicine cabinet. Andrew Rechenberg is an economist at the Coalition for a Prosperous America.